1.
Bioorg Med Chem Lett
; 17(4): 874-8, 2007 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17234405
RESUMO
The optimization of potent MCHr1 antagonist 1 with respect to improving its in vitro profile by replacement of the 3,4-methylenedioxy phenyl (piperonyl) moiety led to the discovery of 19, a compound that showed excellent MCHr1 binding and functional potencies in addition to possessing superior hERG separation, CYP3A4 profile, and receptor cross-reactivity profiles.